In the past week, SOPH stock has gone down by -3.45%, with a monthly decline of -2.78% and a quarterly plunge of -6.67%. The volatility ratio for the week is 2.10%, and the volatility levels for the last 30 days are 3.19% for SOPHiA Genetics SA The simple moving average for the past 20 days is -4.71% for SOPH’s stock, with a -16.73% simple moving average for the past 200 days.
Is It Worth Investing in SOPHiA Genetics SA (NASDAQ: SOPH) Right Now?
The stock has a 36-month beta value of 1.00. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SOPH is 51.78M, and at present, short sellers hold a 0.06% of that float. On June 20, 2025, the average trading volume of SOPH was 43.16K shares.
SOPH) stock’s latest price update
The stock price of SOPHiA Genetics SA (NASDAQ: SOPH) has dropped by -7.89 compared to previous close of 3.04. Despite this, the company has seen a fall of -3.45% in its stock price over the last five trading days. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC lowered its position in SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) by 30.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,753 shares of the company’s stock after selling 5,886 shares during the quarter. Squarepoint Ops LLC’s holdings in SOPHiA GENETICS were worth $43,000 at the end of the most recent quarter. Other institutional investors have also recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its stake in shares of SOPHiA GENETICS by 40.5% in the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after purchasing an additional 28,819 shares in the last quarter. Dimensional Fund Advisors LP grew its position in SOPHiA GENETICS by 23.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock worth $68,000 after purchasing an additional 4,115 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock valued at $2,180,000 after acquiring an additional 42,689 shares in the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock. SOPHiA GENETICS Stock Performance NASDAQ SOPH opened at $2.99 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The firm has a market capitalization of $199.39 million, a price-to-earnings ratio of -2.74 and a beta of 1.00. The company’s fifty day moving average is $2.95 and its two-hundred day moving average is $3.26. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.05. SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The business had revenue of $17.78 million for the quarter, compared to the consensus estimate of $16.76 million. Equities research analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year. Wall Street Analyst Weigh In Separately, BTIG Research set a $5.00 target price on shares of SOPHiA GENETICS in a report on Thursday, March 6th. Read Our Latest Research Report on SOPHiA GENETICS About SOPHiA GENETICS (Free Report) SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
Analysts’ Opinion of SOPH
Many brokerage firms have already submitted their reports for SOPH stocks, with Craig Hallum repeating the rating for SOPH by listing it as a “Buy.” The predicted price for SOPH in the upcoming period, according to Craig Hallum is $11 based on the research report published on December 18, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see SOPH reach a price target of $5, previously predicting the price at $10. The rating they have provided for SOPH stocks is “Equal-Weight” according to the report published on August 07th, 2024.
Guggenheim gave a rating of “Buy” to SOPH, setting the target price at $6 in the report published on June 27th of the previous year.
SOPH Trading at -5.64% from the 50-Day Moving Average
After a stumble in the market that brought SOPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.00% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SOPH starting from JURGI CAMBLONG, who proposed sale 43,135 shares at the price of $2.96 back on May 19 ’25. After this action, JURGI CAMBLONG now owns shares of SOPHiA Genetics SA, valued at $127,680 using the latest closing price.
PHILIPPE MENU, the Officer of SOPHiA Genetics SA, proposed sale 7,148 shares at $2.96 during a trade that took place back on May 19 ’25, which means that PHILIPPE MENU is holding shares at $21,158 based on the most recent closing price.
Stock Fundamentals for SOPH
Current profitability levels for the company are sitting at:
- -0.95 for the present operating margin
- 0.68 for the gross margin
The net margin for SOPHiA Genetics SA stands at -0.99. The total capital return value is set at -0.54. Equity return is now at value -60.75, with -40.48 for asset returns.
Based on SOPHiA Genetics SA (SOPH), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -1.34. The debt to equity ratio resting at 0.35. The interest coverage ratio of the stock is -24.85.
Currently, EBITDA for the company is -51.49 million with net debt to EBITDA at 0.73. When we switch over and look at the enterprise to sales, we see a ratio of 2.17. The receivables turnover for the company is 6.28for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.11.
Conclusion
To sum up, SOPHiA Genetics SA (SOPH) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
